Breaking News Instant updates and real-time market news.

MGNX

MacroGenics

$16.44

-0.15 (-0.90%)

07:17
12/10/18
12/10
07:17
12/10/18
07:17

MacroGenics downgraded to Underperform from Outperform at Raymond James

  • 11

    Dec

MGNX MacroGenics
$16.44

-0.15 (-0.90%)

12/04/18
RHCO
12/04/18
DOWNGRADE
Target $75
RHCO
Hold
Tesaro downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Tesaro (TSRO) to Hold from Buy and raised his price target to $75 from $65 after its announcement of being acquired by Glaxo SmithKline (GSK). The analyst believes that the $75 per share offer price is "fair" and expects the deal, which he views as potentially positive for peers and for the biotech tape, to be completed in Q1 of 2019. Lawson anticipates that other companies with DNA damage response targeting drugs such as Sierra Oncology (SRRA), as well as immunoefficiency pipeline peers including MacroGenics (MGNX), Array Biopharma (ARRY), and Deciphera Pharmaceuticals (DCPH) could benefit from the announcement.
09/10/18
BTIG
09/10/18
INITIATION
Target $30
BTIG
Buy
MacroGenics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed MacroGenics with a Buy rating and a price target if $30, saying he is positive on its DART and TRIDENT multi-functional antibodies programs and its Fc Optimization technology that "allows antibodies to interact more strongly with immune effector cells that resolve antibody-antigen complexes". The analyst contends that while the company's monoclonal antibodies, or mAb, development space is "crowded", MacroGenics offers "nearly two decades of tough won experience" and over two years of cash runway to give its "deep pipeline" multiple opportunities to "turn heads".
05/31/18
EVER
05/31/18
INITIATION
Target $33
EVER
Outperform
MacroGenics initiated with an Outperform at Evercore ISI
Evercore ISI initiated MacroGenics with an Outperform and $33 price target.
04/06/18
LEER
04/06/18
INITIATION
Target $35
LEER
Outperform
MacroGenics assumed with an Outperform at Leerink
Leerink analyst Jonathan Chang assumed coverage of MacroGenics with an Outperform rating and $35 price target. The analyst views bispecific antibodies as a promising drug class and believes MacroGenics has one of the broadest and deepest pipelines of proprietary and partnered bispecific antibodies in clinical development. He has a positive view on the stock ahead of "multiple clinical catalysts" expected in 2018/2019.

TODAY'S FREE FLY STORIES

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Powell on changing policy: »

Powell on changing…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BA

Boeing

$362.00

-0.42 (-0.12%)

11:14
11/14/19
11/14
11:14
11/14/19
11:14
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing moves to session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement CUSIP Number data reported »

10-Yr TIPS Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement Offering Amount data reported »

10-Yr TIPS Announcement…

11:10
11/14/19
11/14
11:10
11/14/19
11:10
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

11:07
11/14/19
11/14
11:07
11/14/19
11:07
Hot Stocks
BioMarin sees GAAP break-even or better in 2020 assuming Valoctocogene launch »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

GILD

Gilead

$62.48

-0.85 (-1.34%)

11:05
11/14/19
11/14
11:05
11/14/19
11:05
Options
Gilead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

11:05
11/14/19
11/14
11:05
11/14/19
11:05
General news
Powell:the day of reckoning could be "quite far off," »

Powell:the day of…

USO

United States Oil Fund

$12.05

0.09 (0.75%)

11:00
11/14/19
11/14
11:00
11/14/19
11:00
General news
Crude inventories for week of November 8 »

Crude oil inventories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$263.91

-0.61 (-0.23%)

10:58
11/14/19
11/14
10:58
11/14/19
10:58
On The Fly
Maxim says sell Apple on concern about 2020 iPhone sales »

Maxim analyst Nehal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$237.81

0.17 (0.07%)

10:56
11/14/19
11/14
10:56
11/14/19
10:56
Periodicals
Breaking Periodicals news story on Air Products »

Lombard Odier's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
11/14/19
11/14
10:55
11/14/19
10:55
General news
Powell: the U.S. is the star economy »

Powell: the U.S. is the…

OPTT

Ocean Power

$1.49

-0.005 (-0.33%)

10:55
11/14/19
11/14
10:55
11/14/19
10:55
Conference/Events
Ocean Power to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

AAPL

Apple

$263.82

-0.7 (-0.26%)

, UBER

Uber

$25.97

-0.73 (-2.73%)

10:53
11/14/19
11/14
10:53
11/14/19
10:53
On The Fly
Apple downgrade, Uber upgrade among today's top analyst calls »

Check out today's top…

AAPL

Apple

$263.82

-0.7 (-0.26%)

UBER

Uber

$25.97

-0.73 (-2.73%)

KHC

Kraft Heinz

$31.79

-1.1 (-3.34%)

VZ

Verizon

$59.16

-0.25 (-0.42%)

T

AT&T

$38.93

-0.22 (-0.56%)

TMUS

T-Mobile

$77.04

-0.98 (-1.26%)

ATUS

Altice USA

$26.91

0.07 (0.26%)

BYND

Beyond Meat

$81.24

2.26 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

10:50
11/14/19
11/14
10:50
11/14/19
10:50
General news
More Powell: the long expansions have been a function of getting inflation under control »

More Powell: the long…

VTGN

VistaGen Therapeutics

$0.34

-0.7449 (-68.65%)

10:45
11/14/19
11/14
10:45
11/14/19
10:45
Downgrade
VistaGen Therapeutics rating change  »

William Blair downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$191.00

0.84 (0.44%)

10:45
11/14/19
11/14
10:45
11/14/19
10:45
Options
Cigna call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 22

    Nov

  • 09

    Dec

  • 06

    Feb

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY hit…

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
Breaking General news story  »

Week of 11/8 EIA…

VTGN

VistaGen Therapeutics

$0.33

-0.7525 (-69.35%)

10:38
11/14/19
11/14
10:38
11/14/19
10:38
Downgrade
VistaGen Therapeutics rating change  »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.